F HOFFMAN-LA ROCHE AG has a total of 19 patent applications. It decreased the IP activity by 100.0%. Its first patent ever was published in 2007. It filed its patents most often in China, Malaysia and WIPO (World Intellectual Property Organization). Its main competitors in its focus markets pharmaceuticals, organic fine chemistry and biotechnology are ONKURE INC, BAIOMEJIYAA INC and TIUMBIO CO LTD.
# | Country | Total Patents | |
---|---|---|---|
#1 | China | 3 | |
#2 | Malaysia | 3 | |
#3 | WIPO (World Intellectual Property Organization) | 3 | |
#4 | South Africa | 3 | |
#5 | Canada | 2 | |
#6 | Costa Rica | 2 | |
#7 | Philippines | 2 | |
#8 | Mexico | 1 |
# | Industry | |
---|---|---|
#1 | Pharmaceuticals | |
#2 | Organic fine chemistry | |
#3 | Biotechnology | |
#4 | Computer technology | |
#5 | Measurement | |
#6 | Environmental technology |
# | Name | Total Patents |
---|---|---|
#1 | Dolente Cosimo | 3 |
#2 | Schnider Patrick | 3 |
#3 | Yan Shixiang | 2 |
#4 | Shen Hong | 2 |
#5 | Zhang Zhisen | 2 |
#6 | Hu Taishan | 2 |
#7 | Kou Buyu | 2 |
#8 | Klein Christian | 2 |
#9 | Moessner Ekkehard | 2 |
#10 | Umana Pablo | 2 |
Publication | Filing date | Title |
---|---|---|
WO2018013710A1 | Primer extension target enrichment | |
CA2990755A1 | Bispecific anti-ceaxcd3 t cell activating antigen binding molecules | |
CN106573060A | Compositions for treating cancer using PD-1 axis binding antagonists and MEK inhibitors |